Invention Grant
- Patent Title: Pivarubicin and benzarubicin compositions
-
Application No.: US17190317Application Date: 2021-03-02
-
Publication No.: US11666589B2Publication Date: 2023-06-06
- Inventor: Leonard Lothstein , Judith Soberman , Tiffany N. Seagroves
- Applicant: Paradox Pharmaceuticals, Inc.
- Applicant Address: US TN Memphis
- Assignee: Paradox Pharmaceuticals, Inc.
- Current Assignee: Paradox Pharmaceuticals, Inc.
- Current Assignee Address: US TN Memphis
- Agency: Hylton-Rodic Law PLLC
- Main IPC: A61K31/704
- IPC: A61K31/704 ; A61K47/14 ; A61P35/00 ; A61K47/02 ; A61K47/10
Abstract:
The present invention relates to compositions comprising at least one of pivarubicin and benzarubicin, or a pharmaceutically acceptable salt thereof, and methods for using the compositions in the treatment of triple negative breast cancer (TNBC) by administering an effective amount of the compositions to a subject. In some instances, the subject is a mammal, including at least one of human, feline, and canine mammals.
Public/Granted literature
- US20210268007A1 TREATMENT OF TRIPLE NEGATIVE BREAST CANCER Public/Granted day:2021-09-02
Information query
IPC分类:
